{
  "emaEpar": [
    {
      "activeSubstance": "dexrazoxane hydrochloride",
      "conditionIndication": "Savene is indicated for the treatment of anthracycline extravasation.",
      "inn": "dexrazoxane",
      "marketingAuthorisationDate": "2006-07-27 00:00:00",
      "marketingAuthorisationHolder": "Clinigen Healthcare B.V.",
      "medicineName": "Savene",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/savene"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Dexrazoxane",
  "nciThesaurus": {
    "casRegistry": "24584-09-6",
    "chebiId": "CHEBI:50223",
    "chemicalFormula": "C11H16N4O4",
    "definition": "A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.",
    "fdaUniiCode": "048L81261F",
    "identifier": "C1333",
    "preferredName": "Dexrazoxane",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C360"
    ],
    "synonyms": [
      "(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)",
      "2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI)",
      "2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)",
      "2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)",
      "2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)",
      "ADR-529",
      "DEXRAZOXANE",
      "Dexrazoxane",
      "ICRF-187",
      "Razoxane (+)-form",
      "Soluble ICRF (L-isomer)",
      "dexrazoxane"
    ]
  }
}